2,4-dichlorobenzyl alcohol
2,4-Dichlorobenzyl alcohol is a mild antiseptic, able to kill bacteria and viruses associated with mouth and throat infections. It is a common ingredient in throat lozenges such as Cofsils, Strepsils, Lorsept, and Gorpils. It is also an ingredient in the European product Neo Borocillina. A low-pH throat lozenge containing dichlorobenzyl alcohol (1.2 mg) and amylmetacresol (0.6 mg) has been found to deactivate respiratory syncytial virus and SARS-Cov, but not adenovirus or rhinovirus. A dentifrice containing 10% sodium benzoate and 0.3% dichlorobenzyl alcohol maintains antimicrobial activity for 5 to 10 minutes after brushing. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Jan 17, 2019 (NCT03944655)
Timeline
No events for the selected filters.
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- Wikipedia2,4-Dichlorobenzyl alcohol ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06220175 | N/A | Mar 1, 2024 | Carol Davila University of Medicine and Pharmacy |
| NCT03944655 | N/A | Jan 17, 2019 | University of Malaya |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Carol Davila University of Medicine and Pharmacy | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Malaya | Academic/Hospital | 1 | 1 | 1 | 2019 |